Background: Systemic drug delivery in schizophrenia is a major challenge, owing to the Blood-brain Barrier (BBB) and P-glycoprotein related effects. Consequently, herein an attempt is made to systemically deliver the most desirable schizophrenia drug, Quetiapine Fumarate (QF) via non-invasive intranasal route using Nanostructured Lipid Carrier (NLC) approach. Materials and Methods: The desired QF loaded NLCs were developed using central composite statistical design and the developed formulations were monitored for improving QF bioavailability and their brain targeting efficacies. Results: The optimized formulation displayed a 2-fold increase (compared to virgin QF) in ex-vivo nasal diffusion at the 6 th hr, with no sign of structural damage (upon histopathological examinations). While, QF blood-brain ratio showed 10-fold increase for NLCs administered through nasal route (in comparison to intravenous route), thereby supporting prolonged retention of QF at the site of action. Similarly, the concentration of QF (in the brain) delivered via nasal route exhibited 4-fold increment at all-time points thereby supporting a potential nose to brain transport and effective bypassing of BBB. Conclusion: The results obtained infers that non-invasive intranasal route can be used as a potential alternative to conventional treatment options towards efficient management of schizophrenia.
Objective: To develop and evaluate Nevirapine (NVP) Extended release tablets for reducing the dosing frequency using Methylcellulose USP Methocel A15-LV and Hypromellose USP Methocel K4M Premium CR used as rate retarding polymers and Magnesium stearate as lubricant. Methods: Tablets were prepared by using roller compaction technique by employing Quality by Design (QbD) and Design of Experimentation (DoE) to study the effect of various process related parameters like Bulk density, Tapped density, Compressibility index, mesh size and in-vitro release data at 20th hour. Results: Obtained results had suggested that concentration of polymer had shown a potential effect over various process parameters and in-vitro drug release studies suggested that formulated tablets had shown a sustained release up to 24h when compared with marketed formulations. Conclusion: From the obtained results it can be concluded that formulation of Nevirapine ER Tablets employing QbD lead to a single dose per day in the management of HIV/AIDS.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.